Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality

Journal of Clinical Psychiatry

Volumn 61, Issue SUPPL. 3, 2000, Pages 16-21

  Glazer, William M ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; POSTSYNAPTIC RECEPTOR; QUETIAPINE; RISPERIDONE; SEROTONIN;

ARTICLE; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MOTOR DYSFUNCTION; NIGRONEOSTRIATAL SYSTEM; PRIORITY JOURNAL; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SUPERSENSITIVITY; TARDIVE DYSKINESIA;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; BRAIN; CLOZAPINE; DIBENZOTHIAZEPINES; HUMANS; MOVEMENT DISORDERS; PIRENZEPINE; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; RISK FACTORS; RISPERIDONE;

EID: 0034016037     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. McCreadie RG. The Nithsdale schizophrenia surveys: an overview. Soc Psychiatry Psychiatr Epidemiol 1992;24:40-45
2. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993;54:133-139
3. Snyder S, Greenberg D, Yamamura H. Antischizophrenic drugs and brain cholinergic receptors. Arch Gen Psychiatry 1974;31:58-61
4. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-544
5. 2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998;155:921-928
6. Zimbroff DL, Kane JM, Tamminga CA, and the Sertindole Study Group. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997;154:782-791
7. Rubovits R, Klawans HL Jr. Implications of amphetamine-induced stereo-typed behavior as a model for tardive dyskinesia. Arch Gen Psychiatry 1972;27:502-507
8. 2 imbalance. In: Yassa R, Nair NPV, Jeste DV, eds. Neuroleptic Induced Movement Disorders. New York, NY: Cambridge University Press; 1997:141-160
9. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996;153:466-476
10. Simpson GM, Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 1997;17:194-201
11. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40
12. Meibach RC, Marder SR. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
13. 2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 1995;57:103-107
14. Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry 1997;58(suppl 10):13-17
15. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123
16. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418
17. Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997;58(suppl 10):55-62
18. Ereshefsky L, Lacombe S. Pharmacological profile of risperidone. Can J Psychiatry 1993;33(suppl 3):80-88
19. Casey DE. Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 1995;10(suppl 3):105-114
20. Arvanitis LA, Miller BG, and the Seroquel Trial 13 Study Group . Multiple fixed doses of Seroduel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-246
21. Crane GE. Pseudoparkinsonism and tardive dyskinesia. Arch Neurol 1972; 27:426-430
22. Kane JM, Woerner M, Borenstein M, et al. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986;22:254-258
23. Saltz BL, Woerner MG, Kane JM, et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991;266:2402-2406
24. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 patients. Arch Gen Psychiatry 1995;52:756-765
25. Chatterjee A, Chakos M, Koreen A, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 1995;152:1724-1729
26. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 1993;50: 723-733
27. Kane JM, Woerner MG, Pollack S, et al. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993;54:327-330
28. Beasley CM Jr, Dellva MA, Tamura RN, et al. Randomized double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999;174:23-30